Mead Johnson Nutrition (NYSE: MJN) is expected to report Q3 earnings on Oct. 25. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Mead Johnson Nutrition's revenues will grow 4.6% and EPS will compress -6.4%.

The average estimate for revenue is $976.9 million. On the bottom line, the average EPS estimate is $0.73.

Revenue details
 Last quarter, Mead Johnson Nutrition tallied revenue of $1.01 billion. GAAP reported sales were 8.6% higher than the prior-year quarter's $932.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.83. GAAP EPS of $0.81 for Q2 were 27% higher than the prior-year quarter's $0.64 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 63.2%, 150 basis points worse than the prior-year quarter. Operating margin was 24.9%, 60 basis points better than the prior-year quarter. Net margin was 16.4%, 220 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $3.97 billion. The average EPS estimate is $3.10.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 77 members out of 91 rating the stock outperform, and 14 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give Mead Johnson Nutrition a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mead Johnson Nutrition is outperform, with an average price target of $89.46.